Article Text

Download PDFPDF

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
  1. Riikka Havunen1,
  2. Mikko Siurala1,2,
  3. Suvi Parviainen2,
  4. Simona Bramante1,
  5. Dipongor Saha1,
  6. Siri Tähtinen1,
  7. Markus Vähä-Koskela1,
  8. Michael Behr3,
  9. Dirk Nettelbeck3,
  10. Anja Ehrhardt4 and
  11. Akseli Hemminki1,2
  1. Aff1 grid.7737.40000000404102071Cancer Gene Therapy Group, MedicumHaartman Institute, University of Helsinki, Helsinki, Finland Helsinki Finland
  2. Aff2 TILT Biotherapeutics Ltd, Helsinki, Finland Helsinki Finland
  3. Aff3 grid.7497.d0000000404920584German Cancer Research Center (DKFZ), Heidelberg, Germany Heidelberg Germany
  4. Aff4 grid.412581.b0000000090246397Witten/Herdecke University, Witten, Germany Witten Germany

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


The field of T cell therapy of cancer holds great promise, as demonstrated by results obtained in Chimeric Antigen Receptor (CAR) modified T cell therapy of CD19+ leukemia. However, these anti-tumor effects are often limited by T cell tolerance and the immunosuppressive tumor microenvironment. Oncolytic viruses armed with immunostimulatory molecules constitute a potent form of immunotherapy. In essence, the danger signal caused by virus replication, coupled with the actions of the transgene, and effective presentation of tumor epitopes by lysis of the cells, results in a personalized cancer vaccine, manufactured for each patient in their tumor.

Previously, we have identified interleukin 2 (IL-2) and Tumor Necrosis Factor alpha (TNF-α) as the most promising factors to stimulate the graft used in adoptive T cell therapy. Both cytokines are important activators of immune cells and also known for their direct anti-tumor properties. Therefore, we aimed to enhance the efficacy of ACT by coupling it with adenoviruses coding for immunostimulatory cytokines. Notably, these cytokines can cause severe side effects when administered systemically. Previously, we and others have achieved long lasting, high level cytokine expression locally but low level systemically when using armed oncolytic viruses in vivo.


Therefore, we developed oncolytic adenoviruses expressing one or both above mentioned human cytokines (Ad5/3-E2F-D24-hTNF-α, Ad5/3-E2F-D24-hIL-2 and Ad5/3-E2F-D24-hTNF-α-IRES-hIL-2). For more detailed immunological studies in immune competent mouse models, we constructed non-replicative adenoviruses with murine cytokines (Ad5-CMV-mIL-2 and Ad5-CMV-mTNF-α). These viruses were studied in combination with adoptive transfer of OT-1 TCR transgenic T cells to treat C57BL/6 mice bearing B16-OVA melanoma tumors. The animals were administered intraperitoneally with CD8+-enriched OT-1 cells with or without intratumoral injections of cytokine-coding viruses.


Combination treatment with Ad5-CMV-mIL-2 and OT-1 resulted in statistically significant anti-tumor efficacy when compared with either monotherapy or untreated control. In further experiments a triple combination of Ad5-CMV-mIL-2 + Ad5-CMV-mTNF-α and OT-1 T cells improved anti-tumor efficacy was observed over dual agent therapies. Furthermore, in mice bearing two tumors we saw abscopal effect when only one of the tumors was injected with cytokine encoding viruses but reduction in tumor size was detected also in the non-injected tumor.


In summary, these results support the further development of cytokine-armed adenoviruses as facilitators of adoptive T cell therapy.